Clinical Trial Update: Trial of Active Immunotherapy With OBI-833 (Globo H-CRM197) in Advanced/Metastatic Gastric, Lung, Colorectal or Breast Cancer Subjects [Phase 1]

View source ↗

Summary

Phase 1 trial of active immunotherapy OBI-833 (Globo H-CRM197) in metastatic gastric, breast, colorectal, and lung cancer has completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer
• Colorectal Cancer
• Gastric Cancer
• Lung Cancer

Drugs mentioned

• OBI-833 (Globo H-CRM197) (Globo H-CRM197)

Snippet

Sponsor: OBI Pharma, Inc | Conditions: Metastatic Gastric Cancer, Metastatic Breast Cancer | Phase 1 | Status: COMPLETED | Results posted: 2022-10-03